Introduction {#Sec1}
============

Fumarate hydratase (FH) and succinate dehydrogenase are two integral enzyme components of the Krebs cycle, and besides their essential role in the TCA cycle, can act as tumour suppressors (King et al. [@CR15]). The *FH* gene codes for fumarate hydratase (or fumarase; EC 4.2.1.2), which catalyzes the stereospecific, reversible hydratation of fumarate to *L*-malate. The *FH* gene localized at 1q42.1 codes for differentially processed, but sequence-wise identical cytosolic and mitochondrial forms. Whereas the mitochondrial enzyme is part of the TCA cycle, the cytosolic form is thought to utilize fumarate derived from different sources. Deficiency in FH activity causes an impaired energy production by interrupting the flow of metabolites through the Krebs cycle. Accumulation of fumarate is thought to competitively inhibit 2-oxo-glutarate dependent dioxygenases that regulate hypoxia inducible factor (HIF), thus activating oncogenic hypoxia pathways (Ratcliffe, [@CR26]).

Due to their essential role in energy production, enzyme deficiencies result in early onset of severe encephalopathy (Kerrigan et al. [@CR14]). Accordingly, autosomal recessive fumarate hydratase deficiency (FHD) caused by mutations in the FH gene results in fumaric aciduria, and common clinical features observed are hypotonia, failure to thrive, severe psychomotor retardation, seizures, facial dysmorphism and brain malformations. Interestingly, whereas homozygous FH mutations predispose to fumaric aciduria, several heterozygous FH mutations are known to be involved in the autosomal dominant syndrome of multiple cutaneous and uterine leiomyomata (MCUL1) (Tomlinson et al. [@CR30]). Affected individuals develop benign smooth muscle tumours of the skin, and females develop fibroids of the uterus. When co-existing with an aggressive form of renal cell carcinoma (papillary renal type II cancer or renal collecting duct cancer) it is also known as hereditary leiomyomatosis and renal cancer (HLRCC) syndrome. In MCUL1/HLRCC germline mutations in FH are detected in the majority of the screened cases. To date, 107 variants have been described, of which 93 are thought to be pathogenic (Bayley et al. [@CR4]). The most common types are missense mutations (57%), followed by frameshift and nonsense mutations (27%), as well as diverse deletions, insertions and duplications.

Here we present the crystal structure of human fumarase at 1.95 Å resolution and summarize structure-activity correlation between observed mutations and clinical phenotypes.

Materials and methods {#Sec2}
=====================

Expression, purification & crystallization {#Sec3}
------------------------------------------

DNA fragment encoding the fumerase domain of human FH (aa 44-510; GenBank entry 19743875) was subcloned into pNIC28-Bsa4 vector incorporating an N-terminal His~6~-tag. The plasmid was transformed into BL21(DE3)-pRARE, cultured in Terrific Broth at 37°C, and induced with 0.1 mM IPTG overnight at 18°C. Cells were homogenized in lysis buffer (50 mM K-phosphate pH 7.5, 500 mM NaCl, 1 mM TCEP), centrifuged to remove cell debris, and the supernatant was purified by Nickel affinity (HisTrap Crude FF) and size exclusion (HiLoad 16/60 Superdex S200) chromatography. Purified protein was concentrated to 12.6 mg/ml and stored in 10 mM HEPES pH 7.5, 150 mM NaCl, 5% (w/v) glycerol and 0.5 mM TCEP at -80°C. Crystals were grown by vapour diffusion at 20°C in sitting drops mixing 150 nl protein and 150 nl reservoir solution containing 20% (w/v) PEG 3350, 0.2 M sodium acetate, 10% (w/v) ethylene glycol and 100 mM Bis-Tris propane pH 7.5. Crystals were cryo-protected in mother liquor containing 25% (w/v) glycerol and flash-frozen in liquid nitrogen.

Data collection & structure determination {#Sec4}
-----------------------------------------

Diffraction data to maximum resolution of 1.95 Å were collected on beamline X10A at the Swiss Light Source, and processed using the CCP4 Program suite (CCP4, [@CR7]). FH crystallized in the trigonal space group P3~2~21 (*a* = 180.5 Å, *b* = 180.5 Å, *c* = 114.6 Å, α = 90^o^, β = 90^o^, γ = 120^o^) with four molecules in the asymmetric unit. The structure of FH was solved by molecular replacement with PHASER (McCoy et al. [@CR18]), using the yeast fumerase structure as search model (PDB code 1YFM). Initial automated model building was performed with ARP/wARP (Perrakis et al. [@CR23]). This is followed by cycles of iterative manual model building using COOT (Emsley & Cowtan [@CR12]) and restrained refinement using REFMAC5 with TLS parameters (Murshudov et al. [@CR22]). The final structure was deposited in the Protein Data Bank ([www.rcsb.org](http://www.rcsb.org)) under accession code 3E04 (Table [1](#Tab1){ref-type="table"}). Table 1X-ray data collection and refinement statisticsData collection Space groupP3~2~21 a, b, c (Å)188.5, 188.5, 114.6 γ120^o^ Wavelength (Å)1.000 Resolution (Å)^\*^25.0 -- 1.95 (2.06 -- 1.95) R~merge~ (%)^\*^0.141 (0.732) I/σI^\*^9.7 (2.0) Completeness (%)^\*^99.3 (96.8) Redundancy^\*^6.2 (5.0)Refinement Resolution (Å)41.27 -- 1.90 No. reflections168629 R~work~/R~free~ (%)19.7/24.4 No. atoms  Protein13160  Ligand/ion12  Water655 B-factors (Å^2^)  Main-chain24.88  Side-chain and water25.91 RMS deviations  Bond lengths (Å)0.010  Bond angles (°)1.201 PDB code3E04 (doi:10.2210/pdb3e04/pdb)^\*^ Numbers in parentheses represent data in the highest resolution shell.

Results and discussion {#Sec5}
======================

Fumarases are divided into two distinct groups. Class I fumarases are iron-dependent iron-sulfur cluster containing, dimeric enzymes, whereas the class II enzymes, including human and other eukaryotic fumarases, are homotetrameric enzymes with a molecular mass of about 200 kDa. Class II fumarases are evolutionarily highly conserved enzymes, e.g. the pairwise identity between *E. coli* and human fumarase is about 60%. Every monomer exhibits a typical tridomain structure, with a central domain involved in subunit interaction, thus forming a typical bundle comprised of 20 α-helices (Fig. [1A](#Fig1){ref-type="fig"}). Previous crystallographic analyses have revealed two distinct sites (A and B) in *E. coli* fumarase that can bind carboxylic acids. Site A is formed from three different monomer chains and likely to be the catalytic site, whereas site B is thought to allosterically regulate activity (Rose and Weaver [@CR28]). Fig. 1Ribbon/surface diagram of human fumarate hydratase illustrating the tetrameric assembly of class II fumarases. Molecular surface representation is used to convey the overall shape of each monomer as well as the tetrameric assembly. Each monomer has been coloured distinctively, to facilitate visualization. Two monomers are represented using semi-transparent surfaces, to highlight the fold (represented as ribbons). One of the active sites is highlighted in red, showing contribution of three distinct subunits. The figures were generated using the program ICM ([www.molsoft.com](http://www.molsoft.com))

A previous study correlated 27 distinct missense mutations to the *E. coli* fumarase structure (Alam [@CR2]), since then the list of mutations has doubled. To this end, 55 missense mutations in the human fumarase gene are now described. Here we correlate this updated list of mutations to fumarase deficiency, MCUL1 and HLRCC syndrome (Table [2](#Tab2){ref-type="table"}) by using the human fumarase structure. Although not all of these novel mutations have been biochemically characterized, previous results suggest that FH activity is related to HLRCC (Alam [@CR1]), although other environmental or genetic factors likely play a role in the etiology of the disease. The clustering of mutational "hotspots" suggests enzyme activity relationships to phenotypic appearances. Figure [2](#Fig2){ref-type="fig"} illustrates the clustering of *FH* mutations observed in FHD, MCUL1 and HLRCC. The large majority of mutations are located at evolutionarily highly conserved positions (Table [2](#Tab2){ref-type="table"}) indicating that these mutations likely affect stability and/or activity of the enzyme. Two major clusters of mutations are observed; one is likely to affect structural integrity of the enzyme by interrupting inter or intrasubunit interactions (indicated in yellow in Fig. [2](#Fig2){ref-type="fig"}), whereas the other mutations are located around the active site and likely directly affect activity. Table 2Mutations observed in the human fumarase gene and association to disease. Abbreviations: CL: cutaneous leiomyoma; FHD: fumarate hydratase deficiency; HLRCC: hereditary leiomyomatosis and renal cell cancer; LCT: Leydig cell tumors; MCUL: multiple cutaneous and uterine leiomyomata; OMC: ovarian mucinous cystadenoma; RCC: renal cell carcinoma; STS: soft tissue sarcoma; UL: uterine leiomyomas; ULMS: uterine leiomyosarcoma\#Mutation siteMutated residueProtein changeDNA changeExonConservationLocalizationReferencePhenotype1Arg51GluR51Ec.152 G \> A2ConservedSurface(Kiuru et al. [@CR16])STS2Arg101ProR101Pc.302 G \> C3Semi-conservedSurface(Chan et al. [@CR8]), (Heinritz et al. [@CR13])HLRCC3Asn107ThrN107Tc.320A \> C3ConservedActive site(Tomlinson et al. [@CR30]), (Alam et al. [@CR1]), (Carvajal-Carmona et al. [@CR6])MCUL, LCT4Ala117ProA117Pc.349 G \> C3Semi-conservedNear active site(Tomlinson et al. [@CR30])MCUL5Leu132SerL132Sc.395 T \> C4Semi-conservedSurface(Wei et al. [@CR32])HLRCC, reduced FH activity6His135ArgH135Rc.404A \> G4Semi-conservedSurface(Chuang et al. [@CR9])MCUL7Gln142LysQ142Kc.424 C \> A4ConservedNear active site(Badeloe et al. [@CR3])MCUL8Ser158IleS158Ic.473 G \> T4Semi-conservedNear active site(Martinez-Mir et al. [@CR21])MCUL9Arg160GlyR160Gc.478A \> G4ConservedSurface(Wei et al. [@CR32])MUCL, reduced FH activity10Pro174ArgP174Rc.521 C \> G4Not conservedSurface(Alam et al. [@CR2]), (Zeng et al. [@CR35]), (Pollard et al. [@CR25])FHD11His180ArgH180Rc.539A \> G4Semi-conservedActive site(Tomlinson et al. [@CR30]), (Alam et al. [@CR2])MUCL12Gln185ArgQ185Rc.554A \> G4ConservedActive site(Tomlinson et al. [@CR30])MCUL13Ser187LeuS187Lc.560C \> T5ConservedActive site(Toro et al. [@CR31])MCUL14Asn188SerN188Sc.563A \> G5ConservedActive site(Toro et al. [@CR31])MCUL15Pro192LeuP192Lc.575A \> G5ConservedIn core helice(Chuang et al. [@CR9])MCUL16Met195ThrM195Tc.584 T \> C5ConservedIn core helice(Toro et al. [@CR31])MCUL17His196ArgH196Rc.587A \> G5ConservedIn core helice(Kiuru et al. [@CR16]), (Lehtonen et al. [@CR17])RCC, ULMS18Ile229ThrI229Tc.686 T \> C5Not conservedSurface(Alam et al. [@CR2])MCUL19Lys230ArgK230Rc.689A \> G5ConservedSubunit stabilization(Tomlinson et al. [@CR30]), (Coughlin et al. [@CR10]), (Manning et al. [@CR19])FHD20Arg233CysR233Cc.697 C \> T5ConservedActive site(Rustin et al. [@CR29]), (Chuang et al. [@CR9]), (Wei et al. [@CR32])FHD, HLRCC, MCUL21Arg233HisR233Hc.698 G \> A5ConservedActive site(Tomlinson et al. [@CR30]), (Alam et al. [@CR2]), (Wei et al. [@CR32]), (Chuang et al. [@CR9]), (Toro et al. [@CR31])HLRCC, MCUL22Arg233LeuR233Lc.698 G \> T5ConservedActive site(Chuang et al. [@CR9]), (Toro et al. [@CR31])MCUL23Ala239ThrA239Tc.715 G \> A5ConservedNear active site(Lehtonen et al. [@CR17])UL24Ala274ThrA274Tc.820 G \> A6Not conservedActive site(Ylisaukko-oja et al. [@CR33])OMC25Gly282ValG282Vc.845 G \> T6ConservedActive site(Tomlinson et al. [@CR30]), (Alam et al. [@CR2])MCUL26Ala308ThrA308Tc.922 G \> A7ConservedSurface(Coughlin et al. [@CR10])FHD27Asn310TyrN310Yc.928A \> T7ConservedSurface(Alam et al. [@CR2])MCUL28Phe312CysF312Cc.935 T \> G7ConservedSurface(Coughlin et al. [@CR10])FHD29His318TyrH318Yc.952 C \> T7Semi-conservedIn core helice(Toro et al. [@CR31]), (Martinez-Mir et al. [@CR21])HLRCC30His318LeuH318Lc.953A \> T7Semi-conservedIn core helice(Deschauer et al. [@CR11])FHD31Val322AspV322Dc.964 T \> A7ConservedIn core helice (interaction with 1 other monomer)(Toro et al. [@CR31])MCUL32Thr330ProT330Pc.988A \> C7Semi-conservedIn core helice (interaction with 1 other monomer)(Chuang et al. [@CR9])MCUL33Cys333TyrC333Yc.998 G \> A7Semi-conservedIn core helice (interaction with 1 other monomer)MCUL34Ser334ArgS334Rc.1002 T \> G7ConservedIn core helice (interaction with 1 other monomer)(Badeloe et al. [@CR3])CL35Leu335ProL335Pc.1004 T \> C7ConservedIn core helice(Toro et al. [@CR31])MCUL36Asn340LysN340Kc.1020 T \> A7Semi-conservedIn core helice(Toro et al. [@CR31]), (Wei et al. [@CR32])MCUL37Glu355LysE355Kc.1063 G \> A7ConservedSubunit stabilization(Alam et al. [@CR2])MCUL38Asn361LysN361Kc.1083 T \> A7ConservedActive site(Alam et al. [@CR2])HLRCC-CDC39Glu362GlnE362Qc.1084 G \> C7ConservedActive site(Bourgeron et al. [@CR5])FHD40Ser365GlyS365Gc.1093 G \> A7ConservedActive site(Toro et al. [@CR31]), (Wei et al. [@CR32])MCUL41Ser366AsnS366Nc.1097 G \> A7ConservedActive site (but out)(Toro et al. [@CR31]), (Alam et al. [@CR2])MCUL42Met368ThrM368Tc.1103 T \> C7ConservedActive site(Badeloe et al. [@CR3])MCUL43Pro369SerP369Sc.1105 C \> T7ConservedActive site (but out)(Maradin et al. [@CR20])FHD44Asn373SerN373Sc.1118A \> G8ConservedActive site(Lehtonen et al. [@CR17])HLRCC/clear cell RCC45Gln376ProQ376Pc.1127A \> C8ConservedIn core helice (interaction with 1 other monomer)(Zeman et al. [@CR34]), (Remes et al. [@CR27]), (Phillips et al. [@CR24])FHD46Ala385AspA385Dc.1154 C \> A8Not conservedIn core helice (interaction with 2 other monomers)(Wei et al. [@CR32])MCUL47Val394LeuV394Lc.1180 G \> C8Not conservedIn core helice(Martinez-Mir et al. [@CR21])MCUL48Gly397ArgG397Rc.1189 G \> A8Semi- conservedIn core helice(Alam et al. [@CR2])MCUL49His402CysH402Cc.1207 C \> T8ConservedIn core helice turn (interaction with 2 other monomers)(Phillips et al. [@CR24])FHD50Ser419ProS419Pc.1255 T \> C9ConservedIn core helice(Wei et al. [@CR32])HLRCC51Asp425ValD425Vc.1274A \> T9ConservedIn core helice (interaction with 1 other monomer)(Coughlin et al. [@CR10])FHD52Gln439ProQ439Pc.1316A \> C9Not conservedSurface(Wei et al. [@CR32])HLRCC53Met454IleM454Ic.1362 G \> A9ConservedSubunit interaction(Carvajal-Carmona et al. [@CR6])LCT54Tyr465CysY465Cc.1394A \> G10Semi- conservedSurface(Toro et al. [@CR31])MCUL55Leu507ProL507Pc.1520 T \> C10Semi- conservedSurface near opening active site(Alam et al. [@CR2])MCULFig. 2Clustering of human fumarase missense mutations observed in FHD, MCUL1 and HLRCC. The active site is highlighted in cyan. Positions of amino acid mutations are indicated as small spheres and numbered according to Table [2](#Tab2){ref-type="table"}. The positions around the active site are indicated in red, mutations affecting inter- or intrasubunit interactions are indicated in dark yellow. For clarity, one monomeric subunit is omitted
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